Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries....

Descripción completa

Detalles Bibliográficos
Autores principales: Brodszky, Valentin, Baji, Petra, Balogh, Orsolya, Péntek, Márta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046087/
https://www.ncbi.nlm.nih.gov/pubmed/24832837
http://dx.doi.org/10.1007/s10198-014-0595-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046087/
https://www.ncbi.nlm.nih.gov/pubmed/24832837
http://dx.doi.org/10.1007/s10198-014-0595-3

Ejemplares similares